Strides Pharma Drug Patent Portfolio
Strides Pharma's Family Patents
Recent FDA approvals and tentative approvals for Strides Pharma
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Innovator drugs
Includes innovator drug submissions that appear in FDA approval and tentative approval disclosures.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Dolutegravir; Tenofovir Disoproxil Fumarate; Lamivudine |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | New Combination and New Formulation or New Manufacturer | 14 Sep, 2023 |
| Stavudine; Lamivudine; Efavirenz |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 4 - New Combination | 01 Jun, 2007 |
| Stavudine; Lamivudine |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 4 - New Combination | 13 Mar, 2007 |
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Lamivudine |
SUPPL-8
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Labeling | 14 Dec, 2016 |
| Tenofovir Disoproxil Fumarate |
SUPPL-6
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Labeling | 07 Dec, 2016 |
| Rilpivirine |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 29 Sep, 2015 |
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List